Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

36.1%

26 terminated/withdrawn out of 72 trials

Success Rate

56.7%

-29.8% vs industry average

Late-Stage Pipeline

1%

1 trials in Phase 3/4

Results Transparency

85%

29 of 34 completed trials have results

Key Signals

3 recruiting29 with results19 terminated7 withdrawn

Enrollment Performance

Analytics

Phase 2
24(42.1%)
N/A
18(31.6%)
Phase 1
11(19.3%)
Early Phase 1
3(5.3%)
Phase 4
1(1.8%)
57Total
Phase 2(24)
N/A(18)
Phase 1(11)
Early Phase 1(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (72)

Showing 20 of 72 trials
NCT01617161Not ApplicableActive Not Recruiting

Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

Role: collaborator

NCT02688517Recruiting

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

Role: collaborator

NCT00587886Active Not Recruiting

Estrogen, Diet, Genetics and Endometrial Cancer

Role: collaborator

NCT00578240Active Not Recruiting

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Role: collaborator

NCT03575793Phase 1Completed

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Role: collaborator

NCT04141449Phase 2Active Not Recruiting

A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation

Role: collaborator

NCT02621398Phase 1Completed

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

Role: collaborator

NCT02400190Not ApplicableActive Not Recruiting

The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)

Role: collaborator

NCT01745588Phase 2Completed

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

Role: collaborator

NCT02015104Phase 2Completed

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Role: collaborator

NCT04829383Phase 2Active Not Recruiting

A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

Role: collaborator

NCT04929899Not ApplicableRecruiting

Bright Ideas - CIN Feasibility Study

Role: collaborator

NCT03382158Recruiting

International PPB/DICER1 Registry

Role: collaborator

NCT02324608Not ApplicableCompleted

Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer

Role: collaborator

NCT00634634Phase 1Completed

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

Role: collaborator

NCT00909909Phase 2Active Not Recruiting

Radiation Therapy in Treating Women With Early Stage Breast Cancer

Role: collaborator

NCT02203604Phase 2Terminated

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Role: collaborator

NCT02526498Phase 2Completed

Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery

Role: collaborator

NCT01417286Phase 2Completed

Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer

Role: collaborator

NCT02526511Not ApplicableUnknown

Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors

Role: collaborator